SEATTLE--(BUSINESS WIRE)--Adaptive Biotechnologies, the leader in combining high-throughput sequencing and expert bioinformatics to profile T-cell and B-cell receptors, will present data from a study of more than 400 children with acute lymphoblastic leukemia (ALL), some observed for more than a decade, demonstrating that the company’s immunosequencing platform, available clinically in the United States as the clonoSEQ® Process, can more sensitively detect minimal residual disease (MRD) than flow cytometry, and that MRD detected using this method is predictive of a patient’s ultimate outcome.
Help employers find you! Check out all the jobs and post your resume.
